Premium
The pendulum swings back: Screening for prostate cancer in 2018
Author(s) -
Thompson Ian M.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31555
Subject(s) - medicine , prostate cancer , cancer , disease , prostate , falling (accident) , gynecology , intensive care medicine , oncology , environmental health
Since the advent of PSA testing in the early 1990s, allowing early detection and treatment of prostate cancer, deaths from this disease have been falling. Subsequently, the US Preventive Services Task Force recommended against PSA testing, a decision that led to declines in prostate cancer screening and detection. After more than a decade of declining deaths from prostate cancer, research in this issue of Cancer has discovered that rates of metastatic prostate cancer are now increasing. This finding should prompt physicians to renew their discussions of PSA testing with their patients and, at a national level, calls for an increased focus on clinical trials incorporating new methods of early diagnosis of this disease.See also pages 2801‐14.